| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology and Genetics |
1 Department of Pharmacology and Toxicology, Division of Clinical Pharmacology; 2 Department of Cell Biology; and 3 Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama
Requests for reprints: Ruiwen Zhang, Department of Pharmacology and Toxicology, University of Alabama at Birmingham, VH 113, Box 600, 1670 University Boulevard, Birmingham, AL 35294. Phone: 205-934-8558; Fax: 205-975-9330; E-mail: ruiwen.zhang{at}ccc.uab.edu.
Although genistein has chemopreventive effects in several human malignancies, including cancers of the breast, colon, and prostate, the mechanisms of action are not fully understood. Herein we report novel mechanisms whereby genistein down-regulates the MDM2 oncogene, perhaps explaining some of its anticancer activities. In a dose- and time-dependent manner, genistein reduced MDM2 protein and mRNA levels in human cell lines of breast, colon, and prostate cancer; primary fibroblasts; and breast epithelial cells. The inhibitory effects were found at both transcriptional and posttranslational levels and were independent of tyrosine kinase pathways. We found that the NFAT transcription site in the region between –132 and +33 in the MDM2 P2 promoter was responsive to genistein. At the posttranslational level, genistein induced ubiquitination of MDM2, which led to its degradation. Additionally, genistein induced apoptosis and G2 arrest and inhibited proliferation in a variety of human cancer cell lines, regardless of p53 status. We further showed that MDM2 overexpression abrogated genistein-induced apoptosis in vitro and that genistein inhibited MDM2 expression and tumor growth in PC3 xenografts. In conclusion, genistein directly down-regulates the MDM2 oncogene, representing a novel mechanism of its action that may have implications for its chemopreventive and chemotherapeutic effects.
This article has been cited by other articles:
|
|
 |
|
  V. A. Carroll and M. Ashcroft Regulation of Angiogenic Factors by HDM2 in Renal Cell Carcinoma Cancer Res., January 15, 2008; 68(2): 545 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-T. Wu, W.-C. Chen, S.-K. Liao, C.-L. Hsu, K.-D. Lee, and M.-F. Chen The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy Endocr. Relat. Cancer, September 1, 2007; 14(3): 633 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-H. Chen, J. Fang, H. Li, W. Demark-Wahnefried, and X. Lin Enterolactone induces apoptosis in human prostate carcinoma LNCaP cells via a mitochondrial-mediated, caspase-dependent pathway Mol. Cancer Ther., September 1, 2007; 6(9): 2581 - 2590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dijsselbloem, S. Goriely, V. Albarani, S. Gerlo, S. Francoz, J.-C. Marine, M. Goldman, G. Haegeman, and W. V. Berghe A Critical Role for p53 in the Control of NF-{kappa}B-Dependent Gene Expression in TLR4-Stimulated Dendritic Cells Exposed to Genistein J. Immunol., April 15, 2007; 178(8): 5048 - 5057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Li, Z. Zhang, D. L. Hill, H. Wang, and R. Zhang Curcumin, a Dietary Component, Has Anticancer, Chemosensitization, and Radiosensitization Effects by Down-regulating the MDM2 Oncogene through the PI3K/mTOR/ETS2 Pathway Cancer Res., March 1, 2007; 67(5): 1988 - 1996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Fang, Q. Zhou, X.-l. Shi, and B.-h. Jiang Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells Carcinogenesis, March 1, 2007; 28(3): 713 - 723. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
